ADAMIS PHARMA WKN: A1XA2F ISIN: US00547W2089 Kürzel: CY3B Forum: Aktien Thema: Hauptdiskussion

Mann hört nichts und sieht nichts und es geht nur Abwärts

🍉

🏗

https://finance.yahoo.com/news/adamis-pharmaceuticals-provides-clinical-study-121700351.html

Woher der Anstieg heute👀

Dr. Dennis J. Carlo, President and Chief Executive Officer of Adamis, commented, “We are pleased with the rapid speed at which the trial is currently enrolling. The DSMB will now have the task of evaluating the preliminary data. If deemed acceptable, without safety or clinical issues, the trial will continue. The trial is designed to enroll a total of 248 patients. We have also recently applied for FAST Track designation, which, if granted, will allow for the rapid regulatory filing for this trial, if successful. Enrollment in this trial has recently dramatically increased and will likely continue to do so as patients with COVID-19 have limited treatment options, especially with Omicron and future variants arising. We believe that Tempol would fulfill a significant unmet medical need because of its antiviral and anti-inflammatory mechanisms of action. We intend to provide an update on the DSMB review of the interim analysis as the data is verified and statistical programs are validated. We estimate the meeting will convene in March.”

SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the enrollment and dosing of more than 100 subjects in the Company’s ongoing Phase 2/3 study of Tempol for the treatment of COVID-19. The Data Safety Monitoring Board (DSMB) will now examine clinical and safety data from the first 50 subjects as part of the first interim analysis.

https://finance.yahoo.com/news/adamis-pharmaceuticals-provides-enrollment-subjects-141700930.html

https://seekingalpha.com/article/4480577-adamis-pharmaceuticals-tempol-potential-leading-covid-19-therapeutic?messageid=2800&utm_campaign=4480577&utm_medium=email&utm_source=seeking_alpha&utm_term=RTA+Article+Smart

Die Verkäufe von zimhi beginnen erst diesen Monat. Tempol Studie endet dieses Jahr. Wie dumm muss man sein jetzt zu verkaufen. Adamis verdient ab jetzt Geld. Also das worauf wir gewartet haben.

Ja nix neues Neu ist die fast track

Kann noch paar Monate dauert. https://www.clinicaltrials.gov/ct2/show/NCT04729595?cond=NCT04729595&draw=2&rank=1

Oder auch nicht 😬

Kommt bestimmt nochmal😜

Habs verkauft